Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia.

Blumer J, Berg S, Adamson PC, Loew T, Rossi G, Hastings C.

Pediatr Blood Cancer. 2007 Oct 15;49(5):687-93.

PMID:
17120240
2.

Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.

Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.

Oncologist. 2006 Apr;11(4):409-17.

PMID:
16614237
3.
4.

Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.

Case AS, Rocconi RP, Kilgore LC, Barnes MN.

Gynecol Oncol. 2006 Jun;101(3):499-502. Epub 2006 Jan 10.

PMID:
16406064
5.

Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy.

Heatherington AC, Dittrich C, Sullivan JT, Rossi G, Schueller J.

Clin Pharmacokinet. 2006;45(2):199-211.

PMID:
16485917
7.

A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.

Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J.

Oncologist. 2007 Oct;12(10):1253-63.

PMID:
17962619
8.

Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study.

Kotasek D, Steger G, Faught W, Underhill C, Poulsen E, Colowick AB, Rossi G, Mackey J; Aranesp 980291 Study Group..

Eur J Cancer. 2003 Sep;39(14):2026-34.

PMID:
12957457
9.

A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.

Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R.

Clin Ther. 2003 Nov;25(11):2781-96.

PMID:
14693304
10.
11.

Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis.

Allon M, Kleinman K, Walczyk M, Kaupke C, Messer-Mann L, Olson K, Heatherington AC, Maroni BJ.

Clin Pharmacol Ther. 2002 Nov;72(5):546-55.

PMID:
12426518
12.
13.

Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease.

Lerner G, Kale AS, Warady BA, Jabs K, Bunchman TE, Heatherington A, Olson K, Messer-Mann L, Maroni BJ.

Pediatr Nephrol. 2002 Nov;17(11):933-7. Epub 2002 Sep 14.

PMID:
12432437
14.

Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.

Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K; ARANESP 20030232 Study Group..

Curr Med Res Opin. 2009 Sep;25(9):2109-20. doi: 10.1185/03007990903084164.

PMID:
19601709
15.
16.

An overview of the pharmacokinetic disposition of darbepoetin alfa.

Zamboni WC, Stewart CE.

Pharmacotherapy. 2002 Sep;22(9 Pt 2):133S-140S. Review.

PMID:
12222583
17.

Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.

Herrington JD, Davidson SL, Tomita DK, Green L, Smith RE, Boccia RV.

Am J Health Syst Pharm. 2005 Jan 1;62(1):54-62.

PMID:
15658073
18.

A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.

Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC Jr, Tezcan H, Waples J, Ward J, Yee LK.

Cancer. 2004 Feb 15;100(4):859-68.

PMID:
14770445
19.

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.

Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J; Aranesp 980297 Study Group..

J Natl Cancer Inst. 2002 Aug 21;94(16):1211-20.

PMID:
12189224
20.

Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.

Reed SD, Radeva JI, Daniel DB, Mody SH, Forlenza JB, McKenzie RS, Schulman KA.

Pharmacoeconomics. 2006;24(5):479-94.

PMID:
16706573

Supplemental Content

Support Center